What is Iterum Therapeutics's gross profit margin?

What factors drove the changes in Iterum Therapeutics's revenue and profit?

What is Iterum Therapeutics's latest dividend and current dividend yield?

What were the key takeaways from Iterum Therapeutics’s earnings call?

Did Iterum Therapeutics beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Iterum Therapeutics next quarter?

What guidance did Iterum Therapeutics's management provide for the next earnings period?

What is the revenue and EPS growth rate for Iterum Therapeutics year over year?

**Modest but Encouraging Launch Progress**: 280+ ORLYNVAH prescriptions in first 10 weeks, 100+ unique prescribers.
- **2026 Revenue Guidance**: $5-15M with lean field team of 10 reps + virtual support.
- **Critical Capital Need**: $25-30M operating expenses; must raise funds to sustain growth.
- **Payer Momentum**: 16% insured lives covered, signed Medicare rebate agreement.
- **Physician Engagement**: 60% prescribers wrote multiple scripts; 40% scripts filled via payer process.

**【CEO Summary Section】**
- Launched ORLYNVAH in August 2025, generating 280+ prescriptions through November 12, 2025, with 100+ unique prescribers.
- 2026 net product revenue guidance: $5-15 million, achieved with a reduced field team of 10 reps (originally planned 20 reps).
- Operating expenses for 2026: $25-30 million; current cash runway extends into Q2 2026.
- Must raise capital to continue commercialization; seeking shareholder approval for additional share issuance.

**【CFO Financial Commentary】**
- Q3 2025 net product sales: $400,000 (includes specialty pharmacy stocking).
- Total operating expenses: $8.1 million (Q3 2025) vs. $4.9 million (Q3 2024), driven by commercialization costs.
- Net loss: $9 million (GAAP) / $7.3 million (non-GAAP) for Q3 2025.
- Cash on hand: $11 million as of September 30, 2025; AT-the-market offering raised $2.6 million through November 13, 2025.

**【Q&A Highlights】**
- **Sales Metrics**: 280+ prescriptions, 100+ prescribers, 40% fill rate through specialty pharmacy.
- **Payer Coverage**: 16% of insured lives covered; signed rebate agreement with top Medicare PBM.
- **Field Team Strategy**: 10 in-person reps + virtual reps to cover 20+ high-value territories efficiently.
- **Capital Needs**: Must raise funds to expand into new territories and maintain commercial momentum.
- **Physician Feedback**: 60% of prescribers wrote >1 script; 40% of scripts filled via payer approval process.


Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

ITRM

ITRM fundamentals

You can ask Aime